Effect of adalimumab interventions on general infection among adults: a systematic review and meta-analysis of randomized controlled trials
| Autor: | Yu-Tung Feng, Chi-Tai Lee, Yu-Chun Lin, Yen-Chun Wang, Tao-Hsin Tung |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult medicine.medical_specialty Time Factors 030106 microbiology Cochrane Library Infections Microbiology law.invention Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Virology Internal medicine Psoriasis medicine Adalimumab Humans 030212 general & internal medicine Intervention Duration Randomized Controlled Trials as Topic Dose-Response Relationship Drug business.industry Incidence (epidemiology) Incidence medicine.disease Infectious Diseases Meta-analysis Rheumatoid arthritis Antirheumatic Agents business medicine.drug |
| Zdroj: | Expert review of anti-infective therapy. 19(10) |
| ISSN: | 1744-8336 |
| Popis: | BACKGROUND This study assessed the safety of adalimumab in different dosages and durations of treatment. METHODS We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to explore the infection risk in people who received adalimumab. We searched the Cochrane Library, PubMed, and EMBASE from inception to December 8, 2020. Summary estimates were obtained using meta-analysis with a random-effects model. RESULTS Twenty-one RCTs, considered to be of high quality, were analyzed. We found that there was a risk of infection (RR: 1.10, 95% CI: 1.02-1.18). In the stratified analysis, we found an increase in infection among those that received normal dosage (RR: 1.13, 95% CI: 1.04-1.23), and in patients with psoriasis (RR: 1.13, 95% CI: 1.00-1.35) and rheumatoid arthritis (RR: 1.23, 95% CI: 1.06-1.41), but not in those that received high doses and other criteria. In the meta-regressions, intervention duration was not related to changes in incidence risk. CONCLUSIONS Trials that have a longer treatment duration and higher doses are needed to clarify whether patients that received adalimumab had an elevated risk of general infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|